Camelid antivenom development and potential in vivo neutralization of Hottentotta saulcyi scorpion venom

Maryam Darvisha, Soltan Ahmad Ebrahimib, Delavar Shahbazzadeh a, Kamran-Pooshang Bagheria, Mahdi Behdania, Mohammad Ali Shokrgozarc, * 

a Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran  
b Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran  
c National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

A R T I C L E   I N F O

Article history:
Received 16 August 2015
Received in revised form 17 January 2016
Accepted 21 January 2016
Available online 22 January 2016

Keywords:
Hottentotta saulcyi  
Heavy chain antibody (HC-Ab)  
Scorpion  
Antivenom

A B S T R A C T

Scorpion envenoming is a serious health problem which can cause a variety of clinical toxic effects. Of the many scorpion species native to Iran, Hottentotta saulcyi is important because its venom can produce toxic effects in man. Nowadays, antivenom derived from hyper immune horses is the only effective treatment for severe scorpion stings. Current limitations of immunotherapy urgently require an efficient alternative with high safety, target affinity and more promising venom neutralizing capability. Recently, heavy chain-only antibodies (HC-Abs) found naturally in camelid serum met the above mentioned advantages. In this study, immuno-reactivities of polyclonal antibodies were tested after successful immunization of camel using H. saulcyi scorpion crude venom. The lethal potency of scorpion venom in C57BL/6 mice injected intraperitoneally was determined to be 2.7 mg/kg. These results were followed by the efficient neutralization of lethal activity of H. saulcyi scorpion venom by injection of antivenom and purified IgG fractions into mice intraperitoneally or intravenously, respectively. HC-Ab camelid antivenom could be considered as a useful serotherapeutics instead of present treatment for scorpion envenomation.

© 2016 Published by Elsevier Ltd.

1. Introduction

Scorpion envenoming syndromes are often encountered in numerous tropical and subtropical regions as major medical concerns (Chippaux and Goyffon, 2008). In Iran the largest numbers of scorpion accidents occur mainly in southwestern regions (Pipelzadeh et al., 2007). The toxic effects are of a greater concern in children and the elderly which are either helpless or more prone to adverse effects. Despite many benign scorpion species, a vast number of accidents lead to permanent organ failure or even death (Ismail, 1995; Jalali and Rahim, 2014). The toxicity of envenomation depends on scorpion species, the physiologic reaction of victim and time needed to gain care centers (Saucier, 2004). According to epidemiologic reports, the annual incidence of scorpion accidents in Iran are at least 45,000 cases (Dehghani and Fathi, 2012; Mozaffari et al., 2013) with 19 of these leading to death (Mirshamsi et al., 2011). Hottentotta saulcyi or black tailed scorpion is one of the most medically important scorpion species in Iran, Turkey, Syria, and Iraq (Kovarik et al., 2011; Nejati et al., 2014). The venom of this scorpion like those of other Butidae family is composed of heterogeneous mixture of enzymes and considerably toxic polypeptides (Rodriguez de la Vega and Possani, 2005), that are low (4–7 kDa) in molecular masses (Jalali et al., 2005), are associated with neurotoxic effects and have high affinity for voltage gated ion channels (Possani et al., 2000, Possani, 2013). Pharmacokinetic study of scorpion envenoming using radiolabeled toxin has demonstrated high bioavailability (95%) resulting from a nearly complete absorption and distribution of the toxins from the injection site to the peripheral compartments in a short time causing the clinical severity and emergency (Ismail et al., 1994; Krift and al., 2001). Commercial antivenoms have been used as antidote since 1897 (Chippaux and Goyffon, 1998) and still remain the only life saving option of envenoming induced by scorpion sting. Fabo- therapics, F(ab’)-based antivenoms, composed of purified IgG derivatives from hyper-immune horses sera have been used for venom interaction and subsequent elimination of scorpion venom toxic effect (Brown and Landon, 2010; Chippaux, 2010; Latifi and
2.2. HPLC separation of Hottentotta saulcyi venom

The scorpion venom was collected by electrical stimulation of telson. The crude venom was dissolved in sterile double-distilled water and centrifuged at 10,000 × g for 10 min at 4 °C. The precipitate was discarded and the supernatant stored at −20 °C until needed.

2.2.1. HPLC separation of Hottentotta saulcyi venom

500 μg of crude venom was dissolved in 150 μl of solution A (0.05% TFA in water) and centrifuged at 10,000 × g for 10 min. The supernatant was then applied to a reverse-phase C18 column (250 × 4.6 mm), and separated on a Knauer HPLC. Proteins were eluted at a flow rate of 1.0 ml/min by a gradient of solution B (0.05% TFA in acetonitrile) as follows: 5% B for 5 min, 5%–45% B over 40 min and 45%–60% B over 10 min. The chromatographic run was monitored at 214 and 280 nm, protein fractions were collected, lyophilized, and stored at −20 °C until needed.

2.3. Immunization protocol

A male camel (Camelus dromedarius) was used for the antivenom production against scorpion venom. Before the first injection, pre-immune sera were collected and dromedary received subcutaneous doses ranging from 100 μg to 2 mg of scorpion crude venom in physiological saline solution (PSS) at weekly interval. The first injection was performed using equal volume of crude venom and complete Freund’s adjuvant and booster injections in incomplete Freund’s adjuvant emulsions. After one week of immunization blood sample was taken, serum separated and stored at −20 °C.

2.4. IgG subclasses fractionation

IgG subclasses were obtained by differential adsorption on Hitrap-protein A and G (Qiagen) columns as described previously. Briefly, 2 ml of immune camel sera were applied onto Protein G column. After washing with 20 mM PBS (pH 7.2), IgG3 and IgG1 successful bound the Hitrap-protein G column, while IgG2 subclass was not adsorbed. The IgG3 was eluted with 0.15 M NaCl, 0.58% acetic acid, pH 3.5. IgG1 fraction was eluted with 0.1 M Glycine-HCl, pH 2.7. The unadsorbed IgG2 fraction was loaded on a protein A column and subsequently eluted by buffer A (pH 4.5). All the purified IgG subclasses were immediately neutralized using 1 M Tris pH 9.0, dialyzed and the absorbance was measured at 280 nm. The purity of IgG fractions was determined on 12% SDS-PAGE under reducing conditions. Proteins bands were visualized by staining with Coomassie brilliant blue R-250.

2.5. ELISA assessment

After the last boost, purified polyclonal IgG fractions were tested for humoral immune response evaluation by indirect ELISA. Briefly, 96-well Maxisorb plate (Nunc) was coated with crude venom (5 μg per well diluted in 100 μl carbonate buffer pH 9.6). After overnight incubation at 4 °C, residual protein binding sites were blocked with 2% BSA in PBS solution for 1 h at room temperature (RT). After several washing step with PBS-T (PBS 0.1% Tween-20), various amount of IgG fractions were added to duplicated wells and incubated 1 h at RT. To remove non specific antigen–antibody binding, the wells were extensively washed with PBS-T and subsequently bound camel IgGs were detected by rabbit anti-camel antibody (diluted 1:5000, Sigma) and detection of rabbit antiserum was performed with mouse anti-rabbit conjugated to horseradish peroxidase (HRP) (Sigma) diluted 1:3000 in PBS. Finally, enzymatic substrate tetramethylbenzidine (TMB) (Sigma) was added. The reaction was stopped after 20 min with 50 μl 2 N sulfuric acid and absorption measured at 450 nm.

2.6. In vivo lethality assessment (LD50)

The toxic activity of scorpion venom was assessed by preparation of increasing amount of crude venom dissolved in 150 μl PSS and i.p. injection into C57Bl/6 mice (18–20 g). Control group received similar volume of PSS without venom. The lethality rate was expressed as median lethal dose (LD50) estimated over 24 h after venom injection according to the Probit analysis (Finney, 1971).

2.7. In vivo neutralization assays (ED50)

The antagonism capacity of polyclonal antibodies were assessed by mixing a constant amount of venom lethal dose (2 LD50) and varying amounts of antivenoms or immunoglobulin fractions diluted in PSS, to give a total volume of 150 μl and 200 μl, respectively. The mixtures were pre-incubated at 37 °C for 30 min and injected into groups of four mice. Control groups received 2 LD50 of venom pre-incubated with PSS. Antivenom mixtures were injected intraperitoneally whereas IgG fractions were injected into the tail. The neutralizing potency was expressed as median effective dose